The effects of radiation are known to be potentiated by N-3 polyunsaturated fatty acids, which modulate several signaling pathways, but the molecular mechanisms through which these fatty acids enhance the anticancer effects of irradiation in colorectal cancer (CRC) treatment remain poorly elucidated. Here, we aimed to ascertain whether the fatty acid docosahexaenoic acid (DHA) exerts a modulating effect on the response elicited by radiation treatment (RT). Two CRC cell lines, Caco-2 and HT-29, were exposed to RT, DHA, or both (DHA + RT) for various times, and then cell viability, proliferation, and clonogenicity were assessed. Moreover, cell cycle, apoptosis, and necrosis were analyzed using flow cytometry, and the involvement of WNT/β-catenin signaling was investigated by immunofluorescence to determine nuclear β-catenin, GSK3β phosphorylation status, and TCF/LEF-activity reporter. DHA and RT applied separately diminished the viability of both HT-29 and Caco-2 cells, and DHA + RT caused a further reduction in proliferation mainly in HT-29 cells, particularly in terms of colony formation. Concomitantly, our results verified cell cycle arrest in G0/G1 phase, a reduction of cyclin D1 expression, and a decrease in GSK3β phosphorylation after the combined treatment. Furthermore, immunofluorescence quantification revealed that nuclear β-catenin was increased in RT-exposed cells, but this effect was abrogated in cells exposed to DHA + RT, and the results of TCF/LEF-activity assays confirmed that DHA attenuated the increase in nuclear β-catenin activity induced by irradiation. Our finding shows that DHA applied in combination with RT enhanced the antitumor effects of irradiation on CRC cells, and that the underlying mechanism involved the WNT/β-catenin pathway. © 2018 BioFactors, 45(1): [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] 2019 
Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer deaths worldwide, with the fourth-highest mortality rate being recorded for this cancer type [1] . Currently, complete surgical resection remains the standard CRC treatment, but this treatment modality is combined with chemotherapy and radiotherapy to improve therapy outcome and reduce therapeutic failure. Despite the radiotherapy protocol designed for CRC leads to a reduction in local relapse the overall survival is not altered [2] .
In radiotherapy, the acquired radioresistance exhibited by surviving cells indicates an adaptive status in which cell-death evasion and tumor progression are increased [3, 4] . In CRC, nuclear β-catenin localization has been demonstrated to represent a marker of radioresistance and adaptation [5, 6] . When the canonical WNT pathway is activated, β-catenin accumulates in the cytoplasm and then translocate into the nucleus, where it activates T-cell factor/lymphoid enhancer factor (TCF/LEF)-mediated transcription of genes involved in cell proliferation and survival and tumor progression [7] . N-3 polyunsaturated fatty acids (N-3 PUFAs) are responsible for regulating the stability, fluidity, and permeability of the cellular membrane, and these fatty acids can also modulate membrane receptors such as EGFR and GRP120 [8] . In addition, N-3 PUFAS can alter enzymatic activity of lypoxygenases, cyclooxygenases, cytochrome P450 monooxygenases, phospholipases and some protein kinases, including mitogen activated protein kinase (MAPK) and protein kinase C (PKC) [9, 10] . Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) exhibit a wide tissue distribution and thus represent the main N-3 PUFA family members [11, 12] . Various lines of evidence indicate that these fatty acids exert beneficial effects in the treatment of several types of cancer, including lung cancer, breast cancer, and, notably, CRC [13] .
Taguchi et al. [14] reported that EPA and DHA can interfere with angiogenic processes and inhibit the effects of vascular and endothelial growth factors. Moreover, CRC cells treated with DHA have been shown to exhibit increased activation of the proapoptotic proteins BAX and BAK and reduced levels of the antiapoptotic proteins Mcl-1 and Bcl-xL [15] . Intriguingly, in liver cancer, breast cancer, and CRC, DHA can promote β-catenin degradation and inhibit proteins involved with death evasion and cell cycle regulation [16] [17] [18] [19] . Moreover, other studies have demonstrated a potential radiosensitizing role of EPA and DHA in CRC cells. For instance, HT-29 cells pretreated with EPA displayed a high degree of radiosensitization, which led to an elevated rate of apoptosis [20] , and application of linoleic acid together with EPA increased the breakdown of tumor DNA in previously irradiated HCT-116 cells [21] . Furthermore, in glioma and lymphoma cells, an additive effect of DHA treatment was observed when combined with irradiation, and this altered the expression of proteins related to radiation response, such as NF-κB, TP53, and Notch1 [22, 23] . However, no study thus far has shown how N-3 PUFA treatment before irradiation affects events related to tumor progression in the case of CRC cells.
In this study, we showed that DHA pretreatment potentiated the effect of irradiation on CRC cells, as evidenced by enhanced inhibition of cell proliferation through a mechanism involving cell cycle arrest, decreased cyclin D1 expression, and reduced activation of the WNT/β-catenin pathway. Thus, our data indicate that DHA treatment can potentially be used in combination with irradiation to inhibit CRC growth and progression.
Materials and methods

Materials
The following antibodies were from commercial sources: rabbit anti-p-GSK3β monoclonal antibody (Ser-9) (5B3, Cat. 
Cell culture
The human colorectal adenocarcinoma cell lines HT-29 (HTB-38TM) and Caco-2 (HTB-37TM) were obtained from American Type Culture Collection (Manassas, VA). The cells were grown in Dulbecco's modified Eagle medium (Invitrogen Inc.) supplemented with 10% fetal bovine serum (FBS), penicillin G (60 mg/L), and streptomycin (100 mg/L) at 37 C in a humidified atmosphere of 5% CO 2 /air, and the cells were passaged weekly by using a solution of 0.05% trypsin/0.02% EDTA in PBS. Caco-2 cells present a differentiated phenotype with low aggressive potential when they form a confluent monolayer, whereas HT-29 cells appear moderately differentiated and exhibit higher tumorigenic potential [24, 25] . For experiments, cells were seeded into culture flasks or on plates or glass coverslips.
DHA pretreatment and exposure to ionizing radiation
DHA was diluted in sterile absolute ethyl alcohol and stock solution of 100 μM stored at −20 C. This stock solution was immediately diluted in DMEM medium to yield the final concentrations before each experiment. HT-29 and Caco-2 cells were grown until they were subconfluent and then treated for 4 h [26] with 15, 25, 50, or 75 μM DHA; subsequently, the cells were exposed to single 5-Gy dose of radiation at 25 C in a 137 Cs γ-irradiator (IBL 437C, CIS Bio International) at a dosage rate of 2.65 Gy/min [6] . Depending of the subsequent assay, the treated and untreated cells were maintained in their own growth medium for 24, 48, or 72 h.
Viability analysis
HT-29 cells (2 × 10 3 /mL) and Caco-2 cells (1 × 10 4 /mL) were seeded and cultured in 96-well plates and, after FBS depletion, were treated with FBS-free medium (control), DHA, 5 Gy of radiation (RT), or a combination of DHA and 5 Gy of radiation (DHA + RT) and maintained for 24, 48, or 72 h. Next, the cells were incubated with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) for 2 h at 37 C, and after washing the formazan crystals were solubilized with DMSO and the absorbance measured at 538 nm was measured using a Spectra Max 190 spectrophotometer (Molecular Devices, Sunnyvale, CA).
Cell-proliferation assay
Cell proliferation was measured using the crystal violet method. 
Clonogenicity assay
HT-29 cells were treated with medium, DHA, RT, or DHA + RT and seeded at a low density (7 × 10 2 cells/mL) in 12-well plates and cultured for 11 days to determine the effects of the treatments on the clonogenic potential of the cells. The colonies that formed were fixed with ethanol for 10 min, stained with a crystal violet solution (0.05% crystal violet and 20% ethanol) for 10 min, washed twice with distilled water, and solubilized with methanol, after which the 595-nm absorbance was measured using a Spectra Max 190 spectrophotometer.
Flow cytometry
For cell cycle analysis, HT-29 cells (1 × 10 6 /mL) cultured in sixwell microtiter plates were FBS-depleted and treated with medium, DHA, RT, and DHA + RT, and 48 h later, the cells were harvested through trypsinization, washed once with icecold PBS, and then stained with 75 μM propidium iodide (PI) for 10 min in a buffer containing 3.4 mM Tris-HCl (pH 7.6), 10 mM NaCl, 0.2% Triton X-100, and 3500 U/L RNase. DNA content was examined by collecting 10,000 events for cell cycle and sub-G1 analyses by using a FACSCalibur flow cytometer (BD Transduction Labs, Lexington, KY) and Mod Fit LT software.
To measure cell death and survival, HT-29 cells (10 6 /mL) were cultured in six-well microtiter plates, serum-starved for 24 h, and then treated with FBS-free medium (control), DHA, RT, or DHA + RT and incubated for 24, 48, or 72 h. Apoptosis was analyzed by using the Annexin V/PI staining assay to detect early and late apoptotic cells and live cells; the cells were washed in ice-cold PBS and resuspended in 100 μL of Annexin V binding buffer (0.1 M Hepes/NaOH (pH 7.4), 1.4 M NaCl, 25 mM CaCl 2 ) containing Annexin V-FITC and PI (1 μg/mL) for 15 min. Samples were analyzed using a FACSCalibur flow cytometer and CellQuest software (BD Biosciences, San Jose, CA).
Immunofluorescence
HT-29 cells (1.2 × 10 6 /mL) were plated on coverslips placed in the wells of 24-well plates, and after treatment with medium, DHA, RT, and DHA + RT, the cells were washed with PBS containing 100 mM CaCl 2 and 100 mM MgCl 2 and then fixed in 100% methanol for 20 min. The samples were permeabilized with 0.5% Triton X-100 in PBS for 10 min, after which the cells were incubated in 50 mM NHCl 4 in PBS for 10 min and blocked in 3% BSA for 1 h. Subsequently, the cells were incubated sequentially with anti-β-catenin primary antibody (1:250) for 1 h, Alexa Fluor 488-conjugated antirabbit secondary antibody for 1 h, and DAPI (1:1000) for 3 min. After the cell monolayers on glass coverslips were washed with PBS and the coverslips were mounted with n-propyl-gallate, the cells were examined and imaged using a confocal laser-scanning microscope, FV10i-O, and the images were analyzed using Fluoview10-ASW software (Olympus, Tokyo, Japan). To quantify β-catenin entry into the nucleus, we examined merged fluorescence images for β-catenin colocalization with DAPI labeling; at least 100 cells were analyzed per condition, and the nuclear β-catenin amount was quantified using Fluoview10-ASW software.
Cell extraction and immunoblotting
For western blotting analysis, cells were homogenized in lysis buffer (1% Triton X-100, 0.5% sodium deoxycholate, 0.2% SDS, 150 mM NaCl, 2 mM EDTA, 10 mM Hepes, pH 7.4) containing 20 mM NaF, 1 mM orthovanadate, and a proteaseinhibitor cocktail (Cat.No.P8340, Sigma; 1:100) for 30 min at 4 C. The lysates were centrifuged at 10,000×g for 10 min at 4 C, the pellets were discarded, and the supernatants were collected and stored at −80 C. Equal amounts of protein (30 μg/lane) mixed with denaturing sample buffer were boiled and then electrophoretically separated using SDS-PAGE (10% or 13% gels) and transferred to nitrocellulose membranes. The membranes were blocked with 5% nonfat milk for 1 h, incubated overnight with primary antibodies against β-catenin (1:4000), phospho-GSK3β (1:1000), total GSK3β (1:1000), and cyclin D1 (1:1000), washed, and then incubated for 1 h with appropriate secondary antibodies for 1 h at room temperature. After washing the membranes, protein bands were visualized using an enhanced chemiluminescence kit (GE Healthcare UK Limited, Buckinghamshire, UK), and the optical densities of the bands were quantified using LabWorks 4.6 software (Bio-Rad Laboratories, Hercules, CA). Where indicated, the membranes were washed and reprobed with antibodies against α-tubulin (1:500) or GAPDH (1:1000), which served as the protein-loading controls.
TCF/LEF transcriptional-activity reporter assay
To analyze the transcriptional activity of β-catenin after the treatments, we measured the TCF/LEF transcription-factor reporter activity by using a Dual-Luciferase Reporter Assay System Kit (Cat.No.E1910, Promega, Madison, WI). Two TCFluciferase reporters were used in the assay: an intact wild-type TCF-luciferase reporter construct (Super 8× TOPFlash), and a mutated TCF-luciferase reporter construct (Super 8× FOPFlash), used as a negative control. HT-29 cells were seeded in 24-well plates and grown until subconfluence, and then the cells were cotransfected transiently with 2 μg each of Super 8× TOPFlash β-Catenin Luciferase reporter and pRL-TK (Renilla luciferase) plasmids or Super 8× FOPFlash β-Catenin Luciferase reporter and pRL-TK plasmids. Transfections were performed using FuGENE ® HD Transfection Reagent (Roche, Pleasanton, CA). After 24 h of transfection, the cells were washed twice with PBS, FBS-depleted for 24 h, and then treated with DHA, RT, DHA + RT, or FBS-free medium (control). The cells were harvested 6 and 24 h after transfection, and extracts were prepared using 200 μL of reporter lysis buffer (Promega). Renilla and firefly luciferase activities were assayed using the DualLuciferase Reporter Assay System Kit (Promega), according to manufacturer instructions. The firefly luciferase activity in each well was normalized relative to the Renilla luciferase activity.
Three independent experiments were performed.
Statistical analysis
Quantitative data are expressed as means AE SEM from at least three independent experiments. Statistical analyses were performed and bar graphs were created using GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA). One-way ANOVA with Bonferroni posttest was applied to compare all treatments. P < 0.05 was considered statistically significant.
Results
DHA treatment differentially reduces the viability of HT-29 and Caco-2 cells
First, we tested how DHA affects cell viability in the CRC cell lines HT-29 and Caco-2 by using the MTT assay. Our results demonstrated that the two cell lines responded distinctly to the DHA stimulus: both cell lines displayed a marked reduction in cell viability at 24 h, but HT-29 cells showed higher sensitivity to DHA treatment, mainly at 48 h (Fig. 1A) ; at this time point, 
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Caco-2 cells did not exhibit a change in viability, and displayed increased viability at 72 h (Fig. 1B) .
DHA potentiates the effects of irradiation on the viability of HT-29 cells
Because we found that DHA treatment reduced cell viability ( Fig. 1) , we evaluated the effect of DHA applied in combination with radiation. Initially, we exposed cells only to γ-radiation and analyzed cell viability by using the MTT assay. HT-29 cells showed a substantial reduction in viability at 48 and 72 h after irradiation (Fig. 2A) ; by contrast, Caco-2 cells showed a reduction in viability at 24 and 48 h, but an increase in viability after 72 h (Fig. 2B) . Next, we assessed how cell viability was affected when DHA was applied together with radiation (DHA + RT); we pretreated HT-29 and Caco-2 cells with 50 μM DHA for 4 h and then exposed the cells to radiation. After 48 h, the viability of HT-29 cells exposed to 50 μM, DHA + RT was significantly lower than that of control cells or cells exposed to RT alone, which indicated that DHA potentiated the effect of radiation (Fig. 2C) . However, this potentiating effect of DHA was not observed in Caco-2 cells (Fig. 2D ).
DHA enhances the irradiation-induced reduction in live HT-29 cells
To further investigate the reduced viability of HT-29 cells that were treated with DHA and then irradiated, we performed Annexin V/PI staining to determine whether the treatments promoted cell death. Flow cytometry analysis revealed that the treatments produced no differences in the populations of early and late apoptotic cells or necrotic cells. However, the total number of live cells was marked lower after exposure to 50 μM DHA + RT than after control treatment ( Fig. 3A and B) .
3.4. DHA potentiates radiation-induced reduction in cell proliferation and clonogenic capacity and promotes cell cycle arrest in G0/G1 phase Next, we analyzed whether the reduction in the population of live cells (Fig. 3 ) occurred due to changes in cell proliferation or cell cycle. The results of cell-proliferation assays, performed using the crystal violet technique, showed that after 48 h, proliferation was substantially diminished in the case of cells pretreated with DHA and exposed to RT (50 μM DHA + RT) as compared with the level measured after other treatments (Fig. 4A) . Moreover, the results of the clonogenicity assay, which is used to evaluate the capacity of cells to proliferate starting from a low density and form new colonies, showed that the combination treatment also drastically reduced the formation of new colonies (Fig. 4B ). To confirm these findings, we used flow cytometry for cell cycle analysis; our results revealed that exposure to 50 μM DHA + RT, as compared with other treatments, significantly increased the G0/G1-phase cell population at 48 h, and this accumulation of cells in the G0/G1 phase was accompanied by a reduction in the cell population in S phase ( Fig. 4C and D) . Collectively, these results indicate that DHA potentiates the effects of RT on cell proliferation and cell cycle.
DHA reduces the level of phosphorylated GSK3β and inhibits β-catenin nuclear translocation in irradiated HT-29 cells
The results of cell cycle analysis indicated that DHA used in combination with RT affected the proliferative capacity of HT-29 cells. Because β-catenin nuclear translocation is a hallmark of WNT/β-catenin pathway activation and this is one of the pathways responsible for tumor progression and responsiveness to radiation exposure in CRC [6, 27] , we analyzed β-catenin subcellular localization after different treatments by using immunofluorescence labeling. At 48 h, cells exposed to RT showed increased β-catenin disorganization at cell-cell contacts and translocation into the nucleus as compared with untreated cells, but cells treated with DHA alone did not show these alterations; notably, however, in cells exposed to DHA + RT, nuclear translocation of β-catenin was attenuated (Fig. 5A and  B) . Next, to investigate the mechanism through which DHA might modulate the dynamics of β-catenin localization, we performed western blotting to examine the phosphorylation status of GSK3β. Our results showed that the level of phosphorylated GSK3β (inactive form) was higher in RT-exposed cells than in untreated cells, whereas this level was decreased in cells exposed to DHA alone and DHA + RT (Fig. 5C) . Together, these results suggest that the WNT/β-catenin pathway is involved in the response to radiation and plays a modulatory role when cells are stimulated with DHA.
DHA attenuates TCF/LEF activity in cells exposed to RT and decreases cyclin D1 expression
Our results showing changes in β-catenin nuclear translocation (Fig. 5) indicated the potential involvement of the WNT/β-catenin pathway in the cellular response to radiation and DHA (C) Representative image of immunoblotting result showing p-GSK-3β (Ser9) and total-GSK-3β in cells exposed to indicated treatments. GAPDH was used as a loading control. Numbers on the bands correspond to results from optical density (OD) analysis, and the score was calculated as the ratio of phospho-GSK3β to total GSK3β. Data were normalized relative to those of control cells and are presented as means AE SEM of triplicate assays from 3 independent experiments. Bar graphs show values normalized as percentages relative to control. One-way ANOVA with post hoc Bonferroni test; ***P < 0.001 versus control.
treatment. To confirm this possibility, we performed TCF/LEF luciferase-reporter assays to directly examine the effect of β-catenin accumulation in the nucleus, where β-catenin acts as cofactor of TCF/LEF. We found that the TCF/LEF reporter activity was significantly increased in RT-exposed cells, but this activity was attenuated in cells exposed to DHA + RT (Fig. 6A) .
Proteins related to cell proliferation are widely recognized to be targets of the WNT/β-catenin pathway [28] . Therefore, considering that DHA + RT exposure caused a reduction in cell proliferation through cell cycle arrest in G0/G1 phase, we analyzed the expression of cyclin D1, a protein involved in the transition from G0/G1 phase to S phase. Whereas cyclin D1 expression was significantly increased in cells exposed to RT, the expression was markedly diminished in cells exposed to DHA + RT (Fig. 6B) . These results showed that DHA attenuated the molecular response elicited by ionizing radiation in CRC cells.
FIG 6
DHA treatment reduces β-catenin transcriptional activity and cyclin D1 expression in HT-29 cells exposed to radiation. Cells were pretreated with 50 μM DHA and 4 h later exposed to gamma-radiation (IR). (A) Treated and control HT-29 cells were used in TCF/LEF luciferase-reporter assays (as described in Materials and Methods) to measure transcriptional activity; β-catenin transcriptional activity was increased in RT-exposed cells, but DHA used in combination with RT significantly attenuated the β-catenin-TCF/LEF activity. Data are presented as means AE SEM of triplicate assays from three independent experiments. Bar graphs show values normalized as percentages relative to control. One-way ANOVA with post hoc Bonferroni test; ***P < 0.01 versus control; # P < 0.05 versus 50 μM DHA + RT. (B) Immunoblotting of cyclin D1. Optical densities (OD) of the band images were measured, and the score was calculated as the ratio of cyclin D1 to α-tubulin values. Data were normalized relative to those obtained for control cells, and the analysis revealed that cyclin D1 expression was increased in RT-exposed cells but the expression was decreased in cells treated with 50 μM DHA + RT.
FIG 7
Schematic diagram of the attenuation of the WNT/β-catenin/cyclin D1 pathway in irradiated cancer colorectal cells through DHA treatment. (A) Radiation promotes reduction of GSK3 β activity allowing the accumulation of β-catenin in the cytoplasm and its translocation to the nucleus where binds to the TCF transcription factor and increases the expression of cyclin D1. (B) DHA in irradiated cells increases GSK3β activity reducing accumulation of β-catenin in the cytoplasm and its subconsequent translocation to the nucleus, decreasing the expression of cyclin D1.
Discussion
Radiation therapy-a critical line of treatment for controlling CRC-acts on cellular pathways involved in cell death, DNA repair, senescence, and changes in cell cycle. Furthermore, when used in combination with others antineoplastic therapies (e.g. chemotherapy), radiotherapy might improve patient survival [4, 29] . However, cancer cells exposed to radiation can develop radioadaptive mechanisms that activate survival pathways [30] , and this potential adaptation can contribute to tumoral repopulation and subsequent cancer relapse [31] . In relation to the search for alternative treatments, N-3 fatty acids are postulated to exert a radiosensitizing effect in the case of various types of cancer cells; however, the molecular mechanisms underlying this radiosensitization, particularly in CRC, remain poorly understood.
We observed that DHA induced a marked reduction in cell viability and that this effect was more prominent in HT-29 cells than Caco-2 cells. Other studies have described this effect in CRC cells and have linked the effect to mechanisms such as upregulation of the cyclin-dependent kinase (CDK) inhibitors p21 and p27 [32] , downregulation of p-ERK [9] , and induction of oxidative stress [33] .
We previously showed that irradiation decreased the viability of CRC cells [6] , although substantial radioresistance was also observed in the study. Thus, we sought to assess whether DHA can potentiate the radiation response of these cells. Intriguingly, our results showed that DHA potentiated the effects of radiation on the viability of HT-29 cells. Furthermore, in HT-29 cells exposed to DHA and RT, apoptotic and necrotic rates were not increased, but a reduction in the population of live cells was observed after exposure to DHA + RT. EPA and DHA were previously reported to potentiate cell death in HT-29 and LS174T cells exposed to radiation, and this was mainly associated with increased expression of heat shock protein 70 and downregulation of the proteins NF-κB p65, COX-2, and Bcl-2 [26] . In A549 lung cancer cells, increased apoptosis was induced by DHA (100 μM) used together with RT, and this effect was related to enhanced oxidative stress, as quantified based on the levels of malondialdehyde, a marker of lipid peroxidation [34] .
Radiation and DHA treatments not only reduce cell survival, but also affect cell proliferation. Here, we found that DHA plus irradiation reduced both the proliferation of HT-29 cells and the ability of the cells to form new colonies. Furthermore, we observed cell cycle arrest in G0/G1 phase accompanied by a decrease in the population of S-phase cells following exposure to DHA + RT. Moreover, comparable results were obtained with irradiated lung cell lines treated with DHA [34] . Other studies have also reported that DHA produces antiproliferative effects in CRC cells, such as by reducing cell growth through cell cycle arrest in G0/G1 phase [35] ; and increasing p21 and stratifin mRNA levels, decreasing CDC25 homolog and CDK-1 levels, and inducing cell cycle arrest in G0/G1 and G2/M phases [36] . In addition, the effects of DHA on cell growth could be directly linked to the antagonism over the cascade of pro-inflammatory eicosanoids promoted by the N-6 PUFA family. Among them the arachidonic acid (AA), the main member of the N-6 PUFA family, is an important substrate to produce eicosanoids. Studies have shown that CACO-2 cells treated with arachidonic acid showed increased prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and 5-, 12-, and 15-hydroxyeicosatetraenoic acid (HETE) and the specific inhibition of these pro-inflammatory mediators blocked the tumor growth, without cytotoxic or apoptotic activity [37] . The N-3 PUFA family competes with AA for access to the cyclooxygenase (COX) and lipoxygenase (LOX) enzymes [38] reducing the pro-inflammatory eicosanoid production load. An interesting study also demonstrated that DHA could suppress cell proliferation and PGE2 formation induced by AA treatment in in LS-174 T cells [39] . However, if this mechanism is occurring in this study remain to be demonstrated.
Nuclear β-catenin has been described as a key protein involved in radioadaptive response, including cell survival when exposed to ionizing radiation [40] . Our immunofluorescence data indicated that β-catenin redistribution from cell-cell contacts to the cytoplasm and β-catenin concentration in the nucleus were elevated in cells exposed to RT, and that this nuclear accumulation of β-catenin was attenuated when DHA was applied in combination with RT. These changes could be directly linked to the phosphorylation status of GSK3β, a protein that plays critical roles in the activation of the WNT/β-catenin pathway [41, 42] . We observed that in cells exposed to DHA + RT, GSK3β phosphorylation was decreased, and, consequently, β-catenin translocation into the nucleus was abrogated. Accordingly, we found that whereas TCF/LEF transcriptional activity was increased in irradiated cells, this was attenuated in cells exposed to DHA + RT. Previous studies had reported that DHA can increase GSK3β activity and reduce TCF/LEF activity in cells such as Hep3B hepatocarcinoma cells [43] , cholangiocarcinoma cells [17] , and pancreatic cancer PANC-1 cells [44] . Interestingly, GSK3β activation increased the radiosensitization of PANC-1 cells, whereas GSK3β silencing increased the expression of β-catenin target genes, measured as the activity levels of the transcription factors AXIN2 and LEF1 [45] . Moreover, in the CRC cell lines HCT-116 and SW480, DHA was demonstrated to induce β-catenin degradation, inhibit nuclear translocation of β-catenin, and reduce the expression of proteins such as Peroxisome proliferator-activated receptor gamma (PPAR-γ), membrane type-1 matrix metalloproteinase-7, and vascular endothelial growth factor [16] .
Nuclear β-catenin accumulation and subsequent activation of the WNT/β-catenin pathway might induce the expression of proteins involved in survival (e.g. survivin) and cell cycle progression (e.g. cyclin D1) and thus exert protumor effects [42, 46] . Here, we observed that cyclin D1 expression was increased in cells exposed to RT and that this was attenuated when DHA was used together with RT. It is known that radiation may increase GSK3β phosphorylation, inhibiting this protein kinase, and to promote growth, cell proliferation and tumor progression. As GSK3β is intimately linked to modulation of the WNT/Beta-catenin/cyclin D1 pathway, the inactivation of GSK3β may result in overexpression of cyclin D1, thus explaining the results here observed [47] .
Interestingly, DHA treatment was previously found to reduce cyclin D1 expression in Caco-2 cells [32] and in MCF7 breast cancer cells, where the treatment also inhibited cell proliferation [18] . Recently, DHA-induced inhibition of cell proliferation in CRC was proposed to be potentially linked to reduced expression of various cell cycle-related proteins, such as cyclins D1, D2, A3, B2, and F [48] . On the other hand, DHA may have seriously affected the cell cycle machinery of cells exposed to radiation via an additive effect on GSK3β activation, modulating the WNT/Beta-catenin pathway and thus to attenuate the accumulation of beta-catenin in the cytoplasm and its nuclear translocation, which may drastically to reduce cyclin D1 expression.
Collectively, our results suggest that DHA might, as in the studies discussed above, modulate the WNT/β-catenin pathway and thus mitigate the effects of irradiation on cell proliferation: DHA could reduce GSK3β phosphorylation and thereby prevent irradiation-triggered nuclear translocation of β-catenin, and therefore preclude the binding of β-catenin with transcription factors and the consequent induction of genes encoding proteins that exhibit protumor properties, such as cyclin D1 (Fig. 7) . Lastly, considering that PUFAs might potentiate the effects of antineoplastic therapies [49, 50] , and that our results showed an additive effect of DHA and irradiation, we suggest that an alternative treatment combining radiation therapy with DHA exposure might be effective for patients with CRC.
